NCT07583251 Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
| NCT ID | NCT07583251 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Pravat Mandal |
| Condition | Mild Cognitive Impairment (MCI) |
| Study Type | INTERVENTIONAL |
| Enrollment | 9 participants |
| Start Date | 2026-06 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 9 participants in total. It began in 2026-06 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
Eligibility Criteria
Inclusion Criteria: 1. Memory complaints; 2. MCI diagnosis 3. MoCA score between 18-25 4. Age 55 - 80 years old. 5. Ability to read and write in English Exclusion Criteria: 1. Subjects with acute head trauma or head injury involving loss of consciousness; 2. Subjects with a history of cancer; 3. Subjects with a history of schizophrenia, manic-depressive disorder 4. Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione) 5. Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence;
Contact & Investigator
Pravat Mandal, PhD
PRINCIPAL INVESTIGATOR
University of Pittsburgh
Frequently Asked Questions
Who can join the NCT07583251 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, up to 80 Years, studying Mild Cognitive Impairment (MCI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07583251 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07583251 currently recruiting?
Yes, NCT07583251 is actively recruiting participants. Contact the research team at mandalpk@pitt.edu for enrollment information.
Where is the NCT07583251 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07583251 clinical trial?
NCT07583251 is sponsored by Pravat Mandal. The principal investigator is Pravat Mandal, PhD at University of Pittsburgh. The trial plans to enroll 9 participants.